REFERENCES
- International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–80.
- Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297–350.
- Benezra D, Cohen E. Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol 1986;70:589–92.
- Kaklamani VG, Kaklamanis PG. Treatment of Behçet’s disease--an update. Semin Arthritis Rheum 2001;30:299–312.
- Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behçet’s disease. J Rheumatol 1990;17:1428–9.
- Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19:S6–12.
- Santos Lacomba M, Marcos Martín C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251–5.
- Turan B, Gallati H, Erdi H et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet’s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128–32.
- Arayssi T, Hamdan A. New insights into the pathogenesis and therapy of Behçet’s disease. Curr Opin Pharmacol 2004;4:183–8.
- Maini SR. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:329–47.
- Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593–610.
- Braun J, Sieper J. Biological therapies in the spondyloarthritides--the current state. Rheumatology (Oxford) 2004;43:1072–84.
- Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001;358:295–6.
- Ohno S, Nakamura S, Hori S et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 2004;31:1362–8.
- Triolo G, Vadalà M, Accardo-Palumbo A et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet’s disease. Ann Rheum Dis 2002;61:560–1.
- Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 2005;52:2478–84.
- Yamada Y, Sugita S, Tanaka H et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010;94:284–8.
- Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008;146:845–50.
- Al-Rayes H, Al-Swailem R, Al-Balawi M et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int 2008;29:53–7.
- Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007;1110:474–84.
- Accorinti M, Pirraglia MP, Paroli MP et al. Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease. Jpn J Ophthalmol 2007;51:191–6.
- Niccoli L, Nannini C, Benucci M at al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford) 2007;46:1161–4.
- Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol 2005;26:83–92.
- Lanthier N, Parc C, Scavennec R et al. Infliximab in the treatment of posterior uveitis in Behçet’s disease. Long term follow up in four patients. Presse Med 2005;34:916–8.
- Wechsler B, Sablé-Fourtassou R, Bodaghi B et al. Infliximab in refractory uveitis due to Behçet’s disease. Clin Exp Rheumatol 2004;22:S14–6.
- Sfikakis PP, Kaklamanis PH, Elezoglou A et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404–6.
- Yazici H, Pazarli H, Barnes CG, Tüzün Y et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990;322:281–5.
- Masuda K, Nakajima A, Urayama A et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989;1:1093–6.